Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fathi

Showing results (101-110 of 168) with videos related to

Pageof 17
Sort By:
Blood|July 27, 2018
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AMLAmir T Fathi, Harry P Erba, Jeffrey E Lancet, et al.
Blood|June 28, 2019
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmarkJustin Taylor, Michael Haddadin, Vivek A Upadhyay, et al.
Blood Advances|November 12, 2021
Coping strategies in patients with acute myeloid leukemiaHermioni L Amonoo, Monica H Bodd, Matthew J Reynolds, et al.
JAMA Oncology|September 8, 2017
Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of MortalityMohamed L Sorror, Barry E Storer, Amir T Fathi, et al.
Blood|December 3, 2017
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemiaEytan M Stein, Roland B Walter, Harry P Erba, et al.
Transplantation and Cellular Therapy|April 12, 2021
Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell TransplantationEvan C Chen, Shuli Li, Ann-Kathrin Eisfeld, et al.
American Journal of Hematology|November 10, 2017
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemiaDaniel J DeAngelo, Andrew M Brunner, Lillian Werner, et al.
The Lancet. Haematology|March 9, 2020
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trialEytan M Stein, Amir T Fathi, Courtney D DiNardo, et al.
Targeted Oncology|April 29, 2024
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 StudyMichael Maris, Gilles Salles, Won Seog Kim, et al.
Blood Advances|April 19, 2024
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndromeCourtney D DiNardo, Gail J Roboz, Justin M Watts, et al.
Pageof 17

Showing results (101-110 of 168) with videos related to

Sort By:
Pageof 17
Blood|July 27, 2018
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AMLAmir T Fathi, Harry P Erba, Jeffrey E Lancet, et al.
Blood|June 28, 2019
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmarkJustin Taylor, Michael Haddadin, Vivek A Upadhyay, et al.
Blood Advances|November 12, 2021
Coping strategies in patients with acute myeloid leukemiaHermioni L Amonoo, Monica H Bodd, Matthew J Reynolds, et al.
JAMA Oncology|September 8, 2017
Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of MortalityMohamed L Sorror, Barry E Storer, Amir T Fathi, et al.
Blood|December 3, 2017
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemiaEytan M Stein, Roland B Walter, Harry P Erba, et al.
Transplantation and Cellular Therapy|April 12, 2021
Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell TransplantationEvan C Chen, Shuli Li, Ann-Kathrin Eisfeld, et al.
American Journal of Hematology|November 10, 2017
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemiaDaniel J DeAngelo, Andrew M Brunner, Lillian Werner, et al.
The Lancet. Haematology|March 9, 2020
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trialEytan M Stein, Amir T Fathi, Courtney D DiNardo, et al.
Targeted Oncology|April 29, 2024
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 StudyMichael Maris, Gilles Salles, Won Seog Kim, et al.
Blood Advances|April 19, 2024
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndromeCourtney D DiNardo, Gail J Roboz, Justin M Watts, et al.
Pageof 17